Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute€Coronar
![Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial | tctmd.com Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial | tctmd.com](https://s3.amazonaws.com/prod.tctmd.com/public/2014-03/123823.png)
Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial | tctmd.com
![Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial | Journal of the American College of Cardiology Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/19ec904e-3df9-4e26-8fa6-57e36b199d6a/j.jacc.2015.11.027.fp.png)
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial | Journal of the American College of Cardiology
![Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial - ScienceDirect Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S193687981630992X-gr3.jpg)
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial - ScienceDirect
![TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com](https://s3.amazonaws.com/prod.tctmd.com/public/styles/large_slide_teaser/public/2015-10/131812.png?itok=oi848V1J)
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
![Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions](https://www.ahajournals.org/cms/asset/ea8c5564-c6b6-4a2e-b86c-5258ac2298e9/e004380fig01.jpeg)
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
![Figure1 | THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | JACC: Journal of the American College of Cardiology Figure1 | THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | JACC: Journal of the American College of Cardiology](https://www.onlinejacc.org/content/65/10_Supplement/A104/F1.large.jpg)
Figure1 | THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | JACC: Journal of the American College of Cardiology
![THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | Journal of the American College of Cardiology THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/0c83e84d-e02f-44bd-98c7-0837d415a420/s0735-1097(15)60104-8.fp.png)
THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | Journal of the American College of Cardiology
![CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications) CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)](https://img.medscapestatic.com/pi/editorial/series/1529975/slide1.png)
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
![Table 5 from Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use | Semantic Scholar Table 5 from Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8954c3685b2bd122a4be1ea110269b2614fc9d80/13-Table5-1.png)